Literature Scan
non-relapse mortality in these patients, the two
combinations have not been compared head-tohead.
A recent open-label, multicenter, randomized, phase III trial conducted by Alessandro
Rambaldi, MD, from the Hematology and Bone
Marrow Transplant Unit at Azienda Ospedaliera
Papa Giovanni XXIII in Bergamo, Italy, and
colleagues compared the safety and efficacy of
busulfan + cyclophosphamide to busulfan +
fludarabine in patients 40 to 65 years old with
AML who had an Eastern Cooperative Oncology Group performance status of less than 3 and
were in complete remission (CR).
Pati